None listed
Conditions
Interventions
None listed
Sponsors
Seoul National University Bundang Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients over 20 years of age Patients who agree to the study and undergo thyroidectomy for thyroid cancer
Exclusion criteria
Exclusion criteria: Patients with diseases other than the thyroid gland Patients who cannot communicate Patients who refused the study Patients with non-thyroid papillary cancer on postoperative biopsy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The BRAF mutation observed in circulatory tumor cells was compared with the final pathological tissue BRAF mutation. About 70-80% of BRAF mutations were observed in the final pathologic examination of thyroid cancer in Korean patients. At this time, it was confirmed that the BRAF mutation of circulating tumor cells was also observed in 70-80%. In addition, it was confirmed that BRAF mutations were observed simultaneously in each | — |
Secondary
| Measure | Time frame |
|---|---|
| The relevance of thyroid cancer by stage. In general, BRAF mutations are observed as the stage of thyroid cancer increases. In other words, we want to confirm whether there is a relationship between the BRAF mutation in circulatory tumor cells and the stage of thyroid cancer. | — |
Countries
Korea, Republic of
Contacts
Public ContactHyeong Won Yu
Seoul National University Bundang Hospital
Outcome results
None listed